On March 14, 2023 Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, reported the presentation of eight posters at the upcoming AACR (Free AACR Whitepaper) Annual Meeting 2023, taking place in Orlando, Florida on April 14-19, 2023 (Press release, Deciphera Pharmaceuticals, MAR 14, 2023, View Source [SID1234628646]). The Company will also host a virtual investor event on Tuesday, April 18 at 6:30 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share new preclinical data that demonstrate the breadth and depth of our research capabilities based on our proprietary switch-control kinase inhibitor platform and its ability to generate new opportunities for potential first- and best-in-class kinase inhibitors," said Steve Hoerter, President and Chief Executive Officer of Deciphera. "At the upcoming AACR (Free AACR Whitepaper) meeting, we look forward to presenting preclinical data supporting our next Investigational New Drug (IND) candidate, DCC-3084, a potential best-in-class pan-RAF inhibitor that broadly inhibits Class I, II, and III BRAF mutations, BRAF fusions, and BRAF/CRAF heterodimers. In addition, we will present preclinical data on our ULK inhibitor, DCC-3116, in combination with QINLOCK in gastrointestinal stromal tumor (GIST) and in combination with encorafenib and cetuximab in colorectal cancer that strongly support two new dose escalation combination studies that we expect to initiate in the second half of this year."

Mr. Hoerter continued, "We continue to expand our leadership position in GIST with the addition of our newest development candidate, DCC-3009, a potential best-in-class pan-KIT inhibitor, which preclinically has demonstrated its ability to potently and very selectively inhibit the broad spectrum of known primary and secondary drug-resistant mutations in GIST, spanning KIT exons 9, 11, 13, 14, 17, and 18. Finally, we are excited to share initial preclinical data on two new programs, GCN2 and PERK, two novel targets focused on the integrated stress response, which is a major adaptive stress response pathway in cancer."

Copies of the abstracts are available on AACR (Free AACR Whitepaper)’s website. Presentation details are as follows:

Poster Number: 4872
Title: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models
Presenter: Madhumita Bogdan, Ph.D., Senior Principal Investigator, Biological Sciences, Deciphera Pharmaceuticals
Session Date: Tuesday, April 18
Session Time: 1:30 – 5:00 PM ET

Poster Number: 1377
Title: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models
Presenter: Madhumita Bogdan, Ph.D., Senior Principal Investigator, Biological Sciences, Deciphera Pharmaceuticals
Session Date: Monday, April 17
Session Time: 9:00 AM – 12:30 PM ET

Poster Number: 4033
Title: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models
Presenter: Bryan Smith, Ph.D., Vice President, Biological Sciences, Deciphera Pharmaceuticals
Session Date: Tuesday, April 18
Session Time: 9:00 AM – 12:30 PM ET

Poster Number: 4045
Title: DCC-3084, a RAF dimer inhibitor, broadly inhibits BRAF class I, II, III, BRAF fusions, and RAS-driven solid tumors leading to tumor regression in preclinical models
Presenter: Stacie Bulfer, Ph.D., Senior Director, Biological Sciences, Deciphera Pharmaceuticals
Session Date: Tuesday, April 18
Session Time: 9:00 AM – 12:30 PM ET

Poster Number: 4938
Title: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, synergizes with asparaginase therapy in leukemic tumors
Presenter: Qi Groer, M.S., Scientist, Biological Sciences, Deciphera Pharmaceuticals
Session Date: Tuesday, April 18
Session Time: 1:30 – 5:00 PM ET

Poster Number: 1639
Title: DP-9149, an investigational small molecule modulator of the Integrated Stress Response kinase GCN2, pre-clinically causes solid tumor growth inhibition as a single agent and regression in combination with standard of care agents
Presenter: Gada Al-Ani, Ph.D., Senior Principal Investigator, Biological Sciences, Deciphera Pharmaceuticals
Session Date: Monday, April 17
Session Time: 9:00 AM – 12:30 PM ET

Poster Number: 1640
Title: DP-9024, an investigational small molecule modulator of the Integrated Stress Response kinase PERK, causes B-cell cancer growth inhibition as single agent and in combination with standard-of-care agents
Presenter: Gada Al-Ani, Ph.D., Senior Principal Investigator, Deciphera Pharmaceuticals
Session Date: Monday, April 17
Session Time: 9:00 AM – 12:30 PM ET

Poster Number: 1613
Title: Dimerization-induced activation of the Integrated Stress Response kinase PERK by an investigational small molecule modulator, DP-9024
Presenter: Aaron Rudeen, Ph.D., Senior Scientist, Deciphera Pharmaceuticals
Session Date: Monday, April 17
Session Time: 9:00 AM – 12:30 PM ET

Conference Call and Webcast

Deciphera will host a virtual investor event on Tuesday, April 18 at 6:30 PM ET. The event may be accessed by registering at View Source A webcast of the event will be available in the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source The archived webcast will be available on the Company’s website within 24 hours after the event and will be available for 30 days following the event.